Windlas Biotech Ltd. (WINDLAS) AI Stock Analysis

• Market Cap: ₹20.10B
• Dividend Yield: 0.63%
• Average Volume (3M): 4.23K
• Price to Earnings (P/E): 30.7
• Beta (1Y): 0.68
• Revenue Growth: 20.19%
• EPS Growth: 8.71%
• Country: IN
• Employees: 1,154
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 8.43
• Shares Outstanding: 21,018,955
• 10 Day Avg. Volume: 3,647
• 30 Day Avg. Volume: 4,226
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,184.00
• Price Target Upside: 12.04% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: ₹1,184.00 ▲(12.04% Upside)

Windlas Biotech Ltd. has a strong financial foundation with robust revenue growth and profitability. Technical indicators show positive momentum, though caution is advised due to the RSI nearing overbought levels. The valuation suggests the stock might be overvalued, which could limit upside potential. Overall, the company is well-positioned but faces valuation challenges.

Windlas Biotech Ltd. Business Overview & Revenue Model

Company Description

Windlas Biotech Ltd. (WINDLAS) is a leading pharmaceutical company based in India, primarily focused on the manufacturing and development of pharmaceutical formulations. The company operates in the pharmaceutical sector, providing a wide range of products including generic drugs, contract manufacturing services, and research and development services for domestic and international markets. Windlas Biotech is known for its expertise in producing solid, liquid, and semi-solid dosage forms and is committed to delivering high-quality and affordable healthcare solutions.

How the Company Makes Money

Windlas Biotech Ltd. generates revenue through a diversified business model that includes contract manufacturing services, sales of branded and generic pharmaceutical products, and research and development services. The company partners with global pharmaceutical companies to provide contract manufacturing services, leveraging its advanced manufacturing capabilities to produce a wide range of pharmaceutical formulations. Additionally, Windlas Biotech earns income from the sale of its own branded and generic products in both domestic and international markets. Strategic partnerships and collaborations with other pharmaceutical companies also play a crucial role in the company's revenue generation, allowing it to expand its product offerings and market reach.

Windlas Biotech Ltd. Financial Statement Overview

Summary

Windlas Biotech Ltd. demonstrates strong financial health with impressive revenue growth and profitability metrics. The balance sheet is solid, with low leverage and high equity, ensuring financial stability. Cash flows are generally healthy, though fluctuations in free cash flow growth should be monitored.

Income Statement

Windlas Biotech Ltd. has shown strong revenue growth over the years with a significant increase from 2024 to 2025. The gross profit margin and EBITDA margin have also improved, indicating efficient cost management and operational performance. The net profit margin is solid, reflecting profitability. However, EBIT margin growth is moderate, suggesting potential areas for operational efficiency improvement.

Balance Sheet

The company maintains a healthy balance sheet with a strong equity position, as evidenced by a favorable equity ratio. The debt-to-equity ratio is low, pointing towards conservative leverage, which limits financial risk. Return on equity is commendable, reflecting effective utilization of shareholder funds. However, the slight increase in total liabilities warrants careful monitoring.

Cash Flow

The cash flow statement shows robust operating cash flow, though there has been a decline from the previous year. Free cash flow remains positive, indicating surplus cash generation. The operating cash flow to net income ratio suggests strong cash earnings quality, although free cash flow growth has been fluctuating, highlighting potential volatility in cash availability.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	7.60B	6.29B	5.11B	4.63B	4.27B
Gross Profit	2.88B	2.28B	1.81B	1.61B	1.52B
EBITDA	1.12B	916.40M	701.91M	591.29M	361.68M
Net Income	609.94M	581.87M	426.26M	380.89M	158.32M
Balance Sheet
Total Assets	7.60B	6.26B	5.29B	4.91B	2.96B
Cash, Cash Equivalents and Short-Term Investments	2.40B	2.04B	1.32B	1.76B	542.55M
Total Debt	325.97M	36.41M	49.93M	66.37M	323.49M
Total Liabilities	2.55B	1.76B	1.27B	962.33M	970.04M
Stockholders Equity	5.06B	4.50B	4.02B	3.95B	1.99B
Cash Flow
Free Cash Flow	159.93M	712.76M	-99.25M	-56.74M	56.07M
Operating Cash Flow	681.87M	1.09B	609.65M	91.30M	114.54M
Investing Cash Flow	-740.64M	-920.68M	-141.10M	-1.55B	-201.98M
Financing Cash Flow	10.13M	-152.90M	-437.39M	1.30B	7.76M

Windlas Biotech Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1056.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WINDLAS, the sentiment is Negative. The current price of 1056.8 is above the 20-day moving average (MA) of 948.47, above the 50-day MA of 919.79, and above the 200-day MA of 959.13, indicating a bearish trend. The MACD of 6.59 indicates Positive momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 16.27 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WINDLAS.

Windlas Biotech Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WINDLAS	74 Outperform	₹20.10B	30.71		0.63%	20.19%	8.71%
SAKAR	68 Neutral	₹7.26B	36.57		―	21.65%	73.84%
SMSPHARMA	61 Neutral	₹20.42B	26.99		0.18%	10.29%	26.79%
BAJAJHCARE	52 Neutral	₹14.64B	32.28		0.22%	17.50%	―
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
INDOCO	47 Neutral	₹26.90B	96.22		0.53%	-8.28%	-247.34%

Windlas Biotech Ltd. Corporate Events

Windlas Biotech Completes Dispatch of Annual Report and AGM Notice

Windlas Biotech Limited has announced the completion of the dispatch of its Annual Report and the Notice of the 24th Annual General Meeting for the financial year 2024-2025. This announcement, made in compliance with SEBI regulations, signifies the company’s adherence to regulatory requirements and its commitment to transparency with its stakeholders. The report and notice have been made available to shareholders, ensuring they are informed about the company’s financial performance and upcoming meeting details.